S.Malathi

A simple, rapid, accurate and precise high performance thin-layer chromatography (HPTLC) method was developed and validated for simultaneous estimation of alogliptin and metformin active pharmaceutical ingredients and fixed dose combination. Alogliptin and metformin densitograms were developed on silica gel 60 F254 HPTLC plates with chloroform: methanol: 0.5 % ammonium sulphate (4:4:2 %v/v) as mobile phase. Densitometric quantification was performed at 254 nm. For Alogliptin and Metformin Rf values were found as 0.66 and 0.44, respectively. The linearity curves of Alogliptin and Metformin were obtained in the concentration range of 100-500 ng/spot and 4000-20000 ng/spot by area with correlation co-efficient of 0.998 and 0.995 for Alogliptin and Metformin, respectively. Limit of detection was found to be 2 ng and 40 ng/spot for Alogliptin and Metformin, respectively; lowest possible quantity to be quantified by the proposed method was found to be 6 ng and 130 ng per spot for Alogliptin and Metformin, respectively. The method was validated for precision, accuracy, specificity and robustness. The developed method was validated and found to be selective, specific and suitable for application in pharmaceutical analysis of these drugs in bulk and fixed dose combination.

A novel reverse phase Ultra performance liquid chromatographic technique was developed for the determination of balofloxacin in bulk and pharmaceutical dosage forms. The method was developed using waters Acquity BEH 50mm, 2.1mm, 2μm, C 18 column with mobile phase containing a gradient mixture of 0.1% phosphoric acid and acetonitrile. Detection was carried out at wavelength 295 nm. The retention time of balofloxacin was 0.89 min. The method showed good linearity in the range 0.5, 1, 1.5,2,3 µg/ml with correlation coefficient for balofloxacin. The proposed method has been validated as per ICH guidelines and successfully applied to the estimation of balofloxacin in their tablet dosage form.